• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases

    7/27/21 4:05:00 PM ET
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARNA alert in real time by email

    Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2

    Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases.

    Under the terms of the agreement, Arena will provide a $60 million upfront payment to Aristea and a $10 million equity investment in Aristea's Series B financing. In return, Aristea has granted Arena an exclusive option to acquire Aristea, including rights to all CXCR2 programs, upon completion of the Phase 2b study of RIST4721 in PPP. The agreement also provides a framework during the option period for the companies to jointly explore the development of additional neutrophil-mediated diseases, including hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD), potentially generating multiple data readouts during the option period.

    Separately, Aristea announced today the closing of a $63 million Series B financing led by Fidelity Management & Research Company, LLC, with participation by existing investor Novo Holdings A/S and new investors Arena Pharmaceuticals and funds managed by Tekla Capital Management, LLC.

    "The collaboration and option agreement with Aristea provides Arena with an opportunity to bolster our early- to mid-stage immunology pipeline in two of our core therapeutic areas, dermatology and gastroenterology," said Amit D. Munshi, President and Chief Executive Officer of Arena Pharmaceuticals. "We look forward to working closely with the Aristea team with the goal of bringing a novel therapy to patients with neutrophilic diseases."

    "This collaboration reflects Arena's commitment to Aristea's highly innovative science, the significant progress we have made in exploring best-in-class therapeutics for serious and rare inflammatory diseases, and the value of our clinical pipeline," said James M. Mackay, Ph.D., Chief Executive Officer of Aristea Therapeutics. "There are currently no approved therapies for PPP in U.S. or EU. Our lead candidate product, RIST4721, has completed a Phase 2a study and it is on track to initiate Phase 2b. We look forward to our productive collaboration with Arena and to accelerating the development of RIST4721 to bring this therapy to patients."

    Conference Call & Webcast Information

    Arena will host a conference call and live webcast to discuss the announcement with the investment community today, Tuesday, July 27, 2021, at 4:45 PM ET. Conference call will be broadcast live in listen-only mode on the company's investor relations website at https://invest.arenapharm.com/events-presentations. To ask questions, please use the dial-in information below:

    Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)

    Conference ID: 7026617

    About RIST4721 and Palmoplantar Pustulosis (PPP)

    RIST4721 is an oral CXCR2 antagonist being developed for the treatment of PPP with results reported from its Phase 2a clinical trial in 2020. PPP is a debilitating condition that is characterized by repeated flares of sterile neutrophil-filled pustules that lead to redness and thickening on the palms of the hands and/or the soles of the feet and associated pain, itching and burning sensations. CXCR2 plays important roles in neutrophil recruitment to inflammatory sites and represents a promising therapeutic target for the treatment of neutrophil-mediated inflammatory diseases. Later this year, Aristea is initiating a Phase 2b study to investigate RIST4721 in PPP and plans to expand development into two additional orphan indications, familial Mediterranean fever (FMF) and Behcet's disease.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done.

    We are developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology, dermatology and cardiology. Our pipeline includes four investigational medicines in eight indications and eleven ongoing or planned clinical trials. To fuel our growth, we are unlocking the value of our historical GPCR research with a sustainable discovery engine for broad portfolio expansion.

    Arena's lead investigational compound in dermatology, etrasimod, is a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator intended to provide systemic and local effects on specific immune cell types with the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn's disease, eosinophilic esophagitis, atopic dermatitis, and alopecia areata.

    ARENA - Care More. Act Differently.

    About Aristea Therapeutics

    Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory orphan diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea's lead program, RIST4721, is currently in Phase 2 clinical development. Aristea is headquartered in San Diego, CA.

    To learn more, please visit www.aristeatx.com and follow us on social media @Aristeatx

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be identified by introductory words such as "development," "option," "will," "opportunity," "potentially," "goal," "look forward to," "promising," "later this year," "investigate," "targeting," "intended to," "plans," "potential," or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, without limitation, statements about the collaboration between Arena and Aristea, including its effectiveness and focus, Arena's exclusive option to acquire Aristea, including rights to all CXCR2 programs, potential data readouts, potential payments to Aristea, and the opportunity and commitment that the collaboration represents; Aristea's science, progress, and pipeline, including the potential to be best-in-class; the potential of Aristea's CXCR2 programs, including the potential development, FDA approval and commercialization of RIST4721 and the potential for RIST4721 to serve as a treatment for PPP, HS, IBD, or other neutrophil mediated diseases; Arena's purpose, work, ideas, execution, portfolio, pipeline, ongoing and planned trials, research, and discovery engine; etrasimod, including its design and potential; and Aristea's focus, partnerships, and pipeline. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's and Aristea's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, without limitation, the following: the collaboration is subject to closing conditions, including regulatory approval, which may not be satisfied or occur; Arena may never exercise its exclusive option to acquire Aristea, including rights to all CXCR2 programs; clinical trials and other studies may not proceed at the time or in the manner expected or at all; enrolling patients in ongoing and intended clinical trials is competitive and challenging; risks related to unexpected or unfavorable new data; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; nonclinical and clinical data are voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena, Aristea, or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the timing and outcome of research, development and regulatory review is uncertain; Arena's and Aristea's ability to obtain financing on favorable terms; Arena's and Aristea's expectations regarding the need to raise additional funds to advance all of their programs; you and others may not agree with the manner in which Arena and Aristea allocate their resources; drug candidates may not advance in development or be approved for marketing; risks related to developing and commercializing drugs, including regulatory, manufacturing and supply issues and the availability and use of RIST4721; risks and uncertainties relating to cash and revenues that may be generated from product sales or other sources, including the impact of competition; risks related to relying on partner performance; risks related to government and other third party actions, including decisions and other actions relating to approval, reimbursement and pricing; our and third parties' intellectual property rights; and satisfactory resolution of litigation or other disagreements with others. With respect to Arena, additional factors that could cause actual results to differ materially from those stated or implied by forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission (SEC), including but not limited to Arena's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Arena and Aristea are providing this information as of the date of this press release, and Arena and Aristea disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210727006087/en/

    Get the next $ARNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARNA

    DatePrice TargetRatingAnalyst
    2/9/2022$120.00 → $100.00Buy → Neutral
    HC Wainwright & Co.
    12/21/2021$93.00 → $100.00Overweight → Neutral
    Cantor Fitzgerald
    12/14/2021Market Outperform → Market Perform
    JMP Securities
    12/14/2021$112.00 → $100.00Outperform → Market Perform
    SVB Leerink
    12/14/2021$76.00 → $100.00Outperform → Sector Perform
    RBC Capital
    12/14/2021$98.00 → $100.00Outperform → Neutral
    Credit Suisse
    12/14/2021$100.00Buy → Hold
    Jefferies
    12/13/2021Buy → Hold
    Needham
    More analyst ratings

    $ARNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:43 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:23 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:23:59 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/11/22 10:07:09 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/9/22 3:24:50 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Arena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ARENA PHARMACEUTICALS INC (0001080709) (Subject)

      2/4/22 9:26:03 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Financials

    Live finance-specific insights

    See more

    $ARNA
    SEC Filings

    See more

    $ARNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets. About Arena Pharmaceuticals ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. ARENA - Care More. Act Differently. Forward-Looking Statements Certain statements in this press relea

      2/9/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer to Acquire Arena Pharmaceuticals

      Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases Expands innovative pipeline potentially enhancing growth through 2025 and beyond Transaction valued at $100 per Arena share in cash, for a total equity value of approximately $6.7 billion Pfizer to host analyst and investor call at 10am EST today with Pfizer I&I executives Pfizer Inc. (NYSE:PFE) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapie

      12/13/21 6:45:00 AM ET
      $ARNA
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Arena Pharmaceuticals Inc.

      15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/21/22 6:03:29 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:11 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Arena Pharmaceuticals Inc.

      EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)

      3/16/22 12:15:08 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. "We are excited to have Dr. Manion join the Arena team," said Mr. Munshi. "Doug has leadership experience across all aspects of research and development, as well as extensive international experience, which will guide Arena R&D as we continue to grow and progress our portfolio." "I was attracted by the breadt

      7/19/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Steven Schoch Elected to Arena Pharmaceuticals Board of Directors

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and technology, including building and scaling businesses and leading innovation. "We are very pleased to have Mr. Schoch join our Board of Directors," said Garry Neil, M.D., Chair of the Board of Directors of Arena. "Steven brings both financial and strategic operational experience that will be of great benefit as Arena prepares for the next stage of growth." Mr. Schoch currently serv

      6/14/21 8:30:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arena Pharmaceuticals downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Arena Pharmaceuticals from Buy to Neutral and set a new price target of $100.00 from $120.00 previously

      2/9/22 6:14:57 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Arena Pharmaceuticals from Overweight to Neutral and set a new price target of $100.00 from $93.00 previously

      12/21/21 5:12:52 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals downgraded by JMP Securities

      JMP Securities downgraded Arena Pharmaceuticals from Market Outperform to Market Perform

      12/14/21 7:04:00 AM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

      – Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. Key Program & Corporate Updates In December announced that Pfizer Inc. and Arena entered into a definitive agreement under which Pfizer has agreed to acquire Arena In November achieved target enrollment for Study A in the Phase 2/3 CULTIVATE trial for etrasimod in Crohn's disease In November the first participant was randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis Phase 3 ELEVATE program

      2/23/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarte

      2/17/22 4:05:00 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care